Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer

NCT01937689 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT01937689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01937689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2013
Completion date
December 31, 2016
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer